Webb'Rechallenge', defined as 'repeated treatment with the same therapeutic class following disease progression in patients who had clinical benefit with prior treatment for … WebbIn the subgroup analysis, the irAE recurrence rate differed according to the irAE type and the ICI regimen. After combination therapy, recurrence occurred most frequently after …
Failure is not final: ctDNA-guided rechallenge therapy in …
Webb21 mars 2024 · Drug-induced liver injury (DILI) is an adverse toxic drug reaction resulting in liver injury. It is an uncommon occurrence with an estimated incidence of 14–19 cases per 100,000 population, accounting for less than 1% of acute liver injury (ALI). 1 Nevertheless, DILI is the most common cause of acute liver failure (ALF) in the West, with a case … WebbSystemic therapy is the main treatment for metastatic prostate cancer. We report a case of docetaxel rechallenge after disease progression. The patient with prostate cancer had multiple bone metastases and lung metastases. The first-line endocrine therapy combined with docetaxel chemotherapy had a satisfactory effect. After the disease progressed, … st mary kansas womens track and field
Osimertinib‐related liver injury with successful osimertinib ...
WebbVA/DoD recommendations ACC/AHA recommendations; Recommend using at least a moderate-dose statin: Initiate or continue moderate-intensity statin therapy in patients … Webb21 Prevention of ADRs …. cont’d • Be aware of the general predisposing factors to ADEs e.g. age, liver and renal disease • Adjust drug therapy to the individual • Ongoing monitoring in high risk patients • Take extra care with drugs known to exhibit a large variety of interactions and adverse reactions (e.g. anti-coagulants, anti-epileptics, hypoglycaemic … Webb16 rader · While rechallenge with targeted therapies has been shown to be associated with an ORR of 47 %, a disease control rate (DCR) of 67 % and a mean progression-free … st mary johnson city tn